Literature DB >> 16782422

Effect of calcium, vitamins K1 and D3 on bone in galactosemia.

Bianca Panis1, Cees Vermeer2, Marinus J P G van Kroonenburgh3, Fred H M Nieman4, Paul P C A Menheere5, Leo J Spaapen6, M Estela Rubio-Gozalbo7.   

Abstract

Classical galactosemia is an inherited disorder of galactose metabolism. Recently, diminished bone mineral content (BMC) in children and adolescents has been found. The aim of this study was to evaluate the effect of calcium, vitamins K(1) and D(3) supplementation on bone in children with galactosemia. A 2-year randomized, double-blind, placebo-controlled clinical trial was undertaken in which 40 children with classical galactosemia (13 males and 27 females, aged 3-17 years) were included to receive daily either 750 mg calcium, 1.0 mg vitamin K(1) and 10.0 microg vitamin D(3) or placebo. BMC of femoral neck, lumbar spine and total body and body composition data were determined by dual energy X-ray absorptiometry (DXA) at baseline and after 1 and 2 years. Diet was assessed using a food frequency questionnaire and a 3-day food diary. Biochemical measurements were determined at baseline and after 1 and 2 years. In the children receiving treatment, carboxylated osteocalcin (cOC) concentration significantly increased (P < 0.001) and undercarboxylated osteocalcin (ucOC) concentration significantly decreased (P = 0.001) when compared to the children receiving placebo. Furthermore, there was a statistically significant increase in BMC of lumbar spine (P = 0.001), lean tissue mass (LTM: P = 0.016) and fat mass (FM: P = 0.014) in the treatment group when compared to the placebo group. The significant increase in cOC and decrease in ucOC concentration in the treatment group were present in prepubertal (P < 0.001 and P = 0.006 respectively) and pubertal children (P = 0.004 and P = 0.042 respectively). The significant increase in BMC of lumbar spine in the treatment group was present only in the prepubertal children (P = 0.015). Supplementation of calcium, vitamins K(1) and D(3) given in this dose (750 mg, 1.0 mg and 10.0 mug respectively) is likely to have a role in the treatment of BMC abnormalities in galactosemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782422     DOI: 10.1016/j.bone.2006.05.002

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  10 in total

Review 1.  Newborn screening for galactosaemia.

Authors:  Rohollah Lak; Bahareh Yazdizadeh; Majid Davari; Mojtaba Nouhi; Roya Kelishadi
Journal:  Cochrane Database Syst Rev       Date:  2017-12-23

2.  Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes.

Authors:  Patricia P Jumbo-Lucioni; Kathryn Garber; John Kiel; Ivo Baric; Gerard T Berry; Annet Bosch; Alberto Burlina; Ana Chiesa; Maria Luz Couce Pico; Sylvia C Estrada; Howard Henderson; Nancy Leslie; Nicola Longo; Andrew A M Morris; Carlett Ramirez-Farias; Susanne Schweitzer-Krantz; Susanne Scheweitzer-Krantz; Catherine Lynn T Silao; Marcela Vela-Amieva; Susan Waisbren; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2012-03-27       Impact factor: 4.982

Review 3.  Primary ovarian insufficiency in classic galactosemia: current understanding and future research opportunities.

Authors:  Mili Thakur; Gerald Feldman; Elizabeth E Puscheck
Journal:  J Assist Reprod Genet       Date:  2017-09-20       Impact factor: 3.412

4.  Bone Health in Classic Galactosemia: Systematic Review and Meta-Analysis.

Authors:  Britt van Erven; Lindsey Welling; Sandra C van Calcar; Artemis Doulgeraki; François Eyskens; Joanna Gribben; Eileen P Treacy; Rein Vos; Susan E Waisbren; M Estela Rubio-Gozalbo; Annet M Bosch
Journal:  JIMD Rep       Date:  2016-12-20

5.  Skeletal health in adult patients with classic galactosemia.

Authors:  L A Batey; C K Welt; F Rohr; A Wessel; V Anastasoaie; H A Feldman; C-Y Guo; E Rubio-Gozalbo; G Berry; C M Gordon
Journal:  Osteoporos Int       Date:  2012-04-19       Impact factor: 4.507

Review 6.  Medical management of chronic liver diseases in children (part I): focus on curable or potentially curable diseases.

Authors:  Mortada H F El-Shabrawi; Naglaa M Kamal
Journal:  Paediatr Drugs       Date:  2011-12-01       Impact factor: 3.022

7.  Revised proposal for the prevention of low bone mass in patients with classic galactosemia.

Authors:  Britt van Erven; Myrna M M Römers; M Estela Rubio-Gozalbo
Journal:  JIMD Rep       Date:  2014-08-03

8.  Newborn screening for galactosaemia.

Authors:  Rohollah Lak; Bahareh Yazdizadeh; Majid Davari; Mojtaba Nouhi; Roya Kelishadi
Journal:  Cochrane Database Syst Rev       Date:  2020-06-22

Review 9.  Sweet and sour: an update on classic galactosemia.

Authors:  Ana I Coelho; M Estela Rubio-Gozalbo; João B Vicente; Isabel Rivera
Journal:  J Inherit Metab Dis       Date:  2017-03-09       Impact factor: 4.982

Review 10.  Bone health in patients with inborn errors of metabolism.

Authors:  M Langeveld; C E M Hollak
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.